索拉非尼治疗门静脉血栓形成的埃及肝癌患者静脉曲张出血初级预防的影响和结果

Al-Azhar International Medical Journal (Print) Pub Date : 2023-01-01 DOI:10.58675/2682-339x.1971

Anwar Abdelaleem Mohamed, Amal Mohamed Mohamed Mahmoud, Mohamed Ashraf Eljaky, Rasha Abdelhafiz Aly, Mohamed Akl Rady

{"title":"索拉非尼治疗门静脉血栓形成的埃及肝癌患者静脉曲张出血初级预防的影响和结果","authors":"Anwar Abdelaleem Mohamed, Amal Mohamed Mohamed Mahmoud, Mohamed Ashraf Eljaky, Rasha Abdelhafiz Aly, Mohamed Akl Rady","doi":"10.58675/2682-339x.1971","DOIUrl":null,"url":null,"abstract":"Background: Patients with cirrhosis and hepatocellular carcinoma (HCC) experience portal hypertension, causing esophageal varices (OV). Some HCC patients taking Sorafenib experience bleeding, while others ignore this effect and believe that sorafenib might minimize bleeding. A comparison was made between carvedilol therapy and primary preventive band ligations in HCC patients with a large, risky OV and portal vein thrombosis (PVT) taking sorafenib. Survival of these patients is also analyzed.","PeriodicalId":474339,"journal":{"name":"Al-Azhar International Medical Journal (Print)","volume":"12 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact and outcome of primary prophylaxis of variceal bleeding among Egyptian hepatocellular carcinoma patients with portal vein thrombosis treated with Sorafenib\",\"authors\":\"Anwar Abdelaleem Mohamed, Amal Mohamed Mohamed Mahmoud, Mohamed Ashraf Eljaky, Rasha Abdelhafiz Aly, Mohamed Akl Rady\",\"doi\":\"10.58675/2682-339x.1971\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Patients with cirrhosis and hepatocellular carcinoma (HCC) experience portal hypertension, causing esophageal varices (OV). Some HCC patients taking Sorafenib experience bleeding, while others ignore this effect and believe that sorafenib might minimize bleeding. A comparison was made between carvedilol therapy and primary preventive band ligations in HCC patients with a large, risky OV and portal vein thrombosis (PVT) taking sorafenib. Survival of these patients is also analyzed.\",\"PeriodicalId\":474339,\"journal\":{\"name\":\"Al-Azhar International Medical Journal (Print)\",\"volume\":\"12 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Al-Azhar International Medical Journal (Print)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.58675/2682-339x.1971\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Al-Azhar International Medical Journal (Print)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.58675/2682-339x.1971","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

背景:肝硬化和肝细胞癌(HCC)患者会出现门静脉高压，导致食管静脉曲张(OV)。一些HCC患者服用索拉非尼会出现出血，而另一些患者则忽略了这种影响，认为索拉非尼可能会减少出血。比较了卡维地洛治疗和一级预防性结扎治疗合并大、危险OV和门静脉血栓形成(PVT)的HCC患者服用索拉非尼的效果。并分析了这些患者的生存情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Impact and outcome of primary prophylaxis of variceal bleeding among Egyptian hepatocellular carcinoma patients with portal vein thrombosis treated with Sorafenib

Background: Patients with cirrhosis and hepatocellular carcinoma (HCC) experience portal hypertension, causing esophageal varices (OV). Some HCC patients taking Sorafenib experience bleeding, while others ignore this effect and believe that sorafenib might minimize bleeding. A comparison was made between carvedilol therapy and primary preventive band ligations in HCC patients with a large, risky OV and portal vein thrombosis (PVT) taking sorafenib. Survival of these patients is also analyzed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Al-Azhar International Medical Journal (Print)

自引率

0.00%

发文量